News

Boston Globe Highlights Cure Alzheimer's Fund Study Linking Anesthetic to Alzheimer's in Mice

Posted: Nov. 12, 2008

Boston Globe story focuses on Cure Alzheimer's Fund study that shows mice given an anesthetic widely used in surgery on people suffered changes to their brains similar to the damage found in Alzheimer's disease. The results by researchers from Dr. Rudy Tanzi of Massachusetts General Hospital was published  in the online Annals of Neurology. The results need to be tested in humans, the authors caution, but the findings raise questions about administering this kind of anesthesia to elderly patients with or without Alzheimer's.

Click here to read the full article

Gene scan of Alzheimer's families identifies four new suspect genes

Posted: Oct. 30, 2008

The first family-based genome-wide association study in Alzheimer’s disease has identified the sites of four novel genes that may significantly influence risk for the most common late-onset form of the devastating neurological disorder.

Cure Alzheimer's Fund's Genome Project Reveals Map of Alzheimer's Genome, Identifies 4 New Genes

Posted: Oct. 29, 2008

Four novel genes that may significantly increase the risk of the most common form of late-onset Alzheimer’s have been identified by researchers at Massachusetts General Hospital and Harvard Medical School, as reported in the November 7th issue of American Journal of Human Genetics. The findings, part of a larger “Alzheimer’s Genome Project” (AGP) established three years ago to identify the full set of Alzheimer’s disease genetic risk factors, may lead to more aggressive therapeutic interventions to slow, stop or even reverse the effects of the disease. These new therapies would differ from current treatments that only address the symptoms of the disease.

Cure Alzheimer's Fund co-sponsors Tomorrow's Leader in Alzheimer's Disease Research Award

Posted: Sep. 24, 2008

The award co-sponsored by the Cure Alzheimer's Fund and the Alzheimer's Association honors the legacies of two pioneering Alzheimer researchers, George G. Glenner and Leon J. Thal.  The two $100,000 grants will be made to early career researchers to inspire and enable innovative research which leads to effective therapies for Alzheimer's Disease.

Major Milestone Achieved

Posted: Aug. 10, 2008

Dr. Rudy Tanzi and his colleagues at Massachusetts General Hospital have identified about 70 genes containing variants that either confer risk, or protect against, Alzheimer's disease in  the Alzheimer's Genome Project™ (AGP).

AGP Pre-Publication Summary by Rudy Tanzi>

Letter from Cure Alzheimer's Fund’s Founders>

Tanzi Discusses "Alzheimer's Genome Project" at International Alzheimer's Conference

Posted: Jul. 22, 2008

Map of Alzheimer’s Genes May Lead to Novel Therapies

Dr. Rudolph Tanzi Speaks at International Conference on Alzheimer’s

Breakthrough genetic research to map all the genes connected to Alzheimer’s, which could lead to more aggressive treatment and a potential cure for the disease, was the focus of a presentation by leading Alzheimer’s researcher Dr. Rudolph Tanzi at the International Conference on Alzheimer’s Disease (ICAD) in Chicago.

Memories are Everything: Alan Arnette wraps up his year long journey

Posted: Jul. 21, 2008

Dear Friends,

It is rare to have an opportunity to combine a personal passion with something critical to the future of your family. Over the past year, I was fortunate to combine my passion for mountain climbing with a global effort to raise awareness and money for Alzheimer’s research.

Isn't Alzheimer's just part of getting old?

Posted: Jul. 21, 2008

No, Alzheimer’s is not a normal part of the aging process.

All parts of our bodies change as we age and this includes the brain. As people get older, they notice slowed thinking and changes in memory. However, the changes in memory associated with Alzheimer’s are not part of normal aging. Alzheimer’s disease is a progressive, irreversible and fatal brain disease.

PBS "The Forgetting: A Portrait of Alzheimer's" Follow up Show

Posted: Jul. 15, 2008

Cure Alzheimer's Fund's Dr. Rudy Tanzi was recently featured on a recent PBS rebroadcast of 2004 Emmy award winning The Forgetting: A Portrait of Alzheimer's.  Tanzi appeared on an expert panel in a newly produced 30-minute follow-up to provide up to the minute perspectives on current Alzheimer’s research, emerging drug therapies and caregiving.

The Forgetting is a pioneering example of how health programming can raise awareness, launch educational initiatives, and offer local connections and resources for viewers and their families.

Click here to view the show

 

Drug Update: Perspective on Two New Alzheimer's Drugs that Have Failed

Posted: Jun. 29, 2008

Two new Alzheimer's drugs, Flurizan (Myriad) and Bapineuzumab (Wyeth/Elan), failed clinical trials. Cure Alzheimer's Fund's Dr. Rudy Tanzi offers some prespective on these drugs.

Read the CNN Money Myriad (Flurizan) press release here

Read the ABC News report on Flurizan

Read the Wyeth/Elan bapineuzumab press release here

Clinical Trial Update
By Dr. Rudolph Tanzi, Massachusetts General Hospital

The results of two clinical trials for Alzheimer’s disease (AD) based on the “amyloid (Αβ) hypothesis of AD” were recently released -- flurizan (Myriad) and bapineuzumab (Wyeth/Elan).  These therapies are aimed at slowing disease progression by curbing the accumulation of Αβ in the brain.